ERBB2 and breast carcinoma: The American Society of Clinical Oncology (ASCO) guidelines already support the use of molecular testing via Oncotype DX, MammaPrint, Breast Cancer Index, and EndoPredict to guide adjuvant endocrine and chemotherapy in select early-stage HR-positive, HER2-negative breast cancer patients with 0–3 positive nodes [56].